Related Experiment Video
Updated: Feb 11, 2026

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
Published on: September 10, 2014
FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer
Mudan Lu1, Xuan Chen2, Jianping Xiao1
1Central laboratory, The Affiliated Wuxi Matemity and Child Health Care Hospital of Nanjing Medical University, Wuxi, China.
Objective:
Ovarian cancer is one of the most serious disease in female reproductive system. Platinum is the first-line drug for the treatment of ovarian cancer, while the resistance of platinum drug in clinical hindered the relief ovarian cancer. Our previous study found that decreased FOXO3a might be a poor prognosis in human ovarian cancer. In this research, we study whether FOXO3a was involved in the mechanism of platinum drug resistance.
Methods:
The CCK-8 and FACS analysis were used to monitor the survival of ovarian cancer, and the FOXO3a expression was detected by western-blot.
Results:
We found that FOXO3a expression upregulated significantly in A2780 compared with A2780/DDP cells with the treatment of platinum. Moreover, overexpression of FOXO3a in ovarian cancer inversed the platinum resistance in ovarian cancer.
Conclusion:
These observations reminded that the role of FOXO3a might be one of the critical mechanisms in developing platinum drug resistance in ovarian cancer.
Insights
Decreased FOXO3a expression is linked to platinum drug resistance in ovarian cancer. Restoring FOXO3a levels can reverse this resistance, offering a potential therapeutic target for improving ovarian cancer treatment.
Area of Science:
- Gynecology
- Oncology
- Molecular Biology
Background:
- Ovarian cancer is a significant threat to female reproductive health.
- Platinum-based chemotherapy is a primary treatment, but drug resistance is a major clinical challenge.
- Previous research indicated that reduced FOXO3a expression may correlate with poor prognosis in ovarian cancer.
Purpose of the Study:
- To investigate the role of FOXO3a in the development of platinum drug resistance in ovarian cancer.
- To determine if FOXO3a expression levels influence the efficacy of platinum-based chemotherapy.
Main Methods:
- Cell viability was assessed using CCK-8 assays.
- Apoptosis and cell cycle analysis were performed using FACS.
- FOXO3a protein expression was quantified via Western blot.
Main Results:
- FOXO3a expression was significantly upregulated in platinum-treated A2780 cells compared to resistant A2780/DDP cells.
- Overexpression of FOXO3a in ovarian cancer cells reversed platinum drug resistance.
- These findings suggest a direct link between FOXO3a levels and platinum sensitivity.
Conclusions:
- FOXO3a plays a critical role in the mechanism of platinum drug resistance in ovarian cancer.
- Modulating FOXO3a expression may represent a novel strategy to overcome chemotherapy resistance.
- Further research into FOXO3a's function could lead to improved ovarian cancer treatment outcomes.
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Ovarian Cycle
Reversible and Irreversible Processes
Diode: Reverse bias

